Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
7,308
archived clinical trials in
Hepatitis

Drug Drug Interaction Study Between BI 201335 and BI 207127 in Chronic Hepatitis C Infected Patients
A Multi-centre, Open Label, Parallel Group Trial to Evaluate the Pharmacokinetic Interactions Between BI 207127 (600 mg t.i.d. or 600 mg b.i.d.) and BI 201335 (120 mg q.d.) Given in Combination With Ribavirin for 24 Weeks, and Their Combined Effect on the Pharmacokinetics of Tenofovir, Raltegravir, Caffeine (the Probe Drug Substrate for CYP1A2), Tolbutamide (the Probe Drug Substrate for CYP2C9) and Midazolam (the Probe Drug Substrate for CYP3A4) in Treatment naïve Patients and Prior Treatment Relapse or Partial Responder Patients With Genotype 1 Chronic Hepatitis C Infection
Status: Enrolling
Updated:  12/10/2013
1218.74.01045 Boehringer Ingelheim Investigational Site
2310
mi
from 98109
Rockville, MD
Drug Drug Interaction Study Between BI 201335 and BI 207127 in Chronic Hepatitis C Infected Patients
A Multi-centre, Open Label, Parallel Group Trial to Evaluate the Pharmacokinetic Interactions Between BI 207127 (600 mg t.i.d. or 600 mg b.i.d.) and BI 201335 (120 mg q.d.) Given in Combination With Ribavirin for 24 Weeks, and Their Combined Effect on the Pharmacokinetics of Tenofovir, Raltegravir, Caffeine (the Probe Drug Substrate for CYP1A2), Tolbutamide (the Probe Drug Substrate for CYP2C9) and Midazolam (the Probe Drug Substrate for CYP3A4) in Treatment naïve Patients and Prior Treatment Relapse or Partial Responder Patients With Genotype 1 Chronic Hepatitis C Infection
Status: Enrolling
Updated: 12/10/2013
1218.74.01045 Boehringer Ingelheim Investigational Site
2310
mi
from 98109
Rockville, MD
Click here to add this to my saved trials
Drug Drug Interaction Study Between BI 201335 and BI 207127 in Chronic Hepatitis C Infected Patients
A Multi-centre, Open Label, Parallel Group Trial to Evaluate the Pharmacokinetic Interactions Between BI 207127 (600 mg t.i.d. or 600 mg b.i.d.) and BI 201335 (120 mg q.d.) Given in Combination With Ribavirin for 24 Weeks, and Their Combined Effect on the Pharmacokinetics of Tenofovir, Raltegravir, Caffeine (the Probe Drug Substrate for CYP1A2), Tolbutamide (the Probe Drug Substrate for CYP2C9) and Midazolam (the Probe Drug Substrate for CYP3A4) in Treatment naïve Patients and Prior Treatment Relapse or Partial Responder Patients With Genotype 1 Chronic Hepatitis C Infection
Status: Enrolling
Updated:  12/10/2013
1222.52.02030 Boehringer Ingelheim Investigational Site
2386
mi
from 98109
Marlton, NJ
Drug Drug Interaction Study Between BI 201335 and BI 207127 in Chronic Hepatitis C Infected Patients
A Multi-centre, Open Label, Parallel Group Trial to Evaluate the Pharmacokinetic Interactions Between BI 207127 (600 mg t.i.d. or 600 mg b.i.d.) and BI 201335 (120 mg q.d.) Given in Combination With Ribavirin for 24 Weeks, and Their Combined Effect on the Pharmacokinetics of Tenofovir, Raltegravir, Caffeine (the Probe Drug Substrate for CYP1A2), Tolbutamide (the Probe Drug Substrate for CYP2C9) and Midazolam (the Probe Drug Substrate for CYP3A4) in Treatment naïve Patients and Prior Treatment Relapse or Partial Responder Patients With Genotype 1 Chronic Hepatitis C Infection
Status: Enrolling
Updated: 12/10/2013
1222.52.02030 Boehringer Ingelheim Investigational Site
2386
mi
from 98109
Marlton, NJ
Click here to add this to my saved trials
Drug Drug Interaction Study Between BI 201335 and BI 207127 in Chronic Hepatitis C Infected Patients
A Multi-centre, Open Label, Parallel Group Trial to Evaluate the Pharmacokinetic Interactions Between BI 207127 (600 mg t.i.d. or 600 mg b.i.d.) and BI 201335 (120 mg q.d.) Given in Combination With Ribavirin for 24 Weeks, and Their Combined Effect on the Pharmacokinetics of Tenofovir, Raltegravir, Caffeine (the Probe Drug Substrate for CYP1A2), Tolbutamide (the Probe Drug Substrate for CYP2C9) and Midazolam (the Probe Drug Substrate for CYP3A4) in Treatment naïve Patients and Prior Treatment Relapse or Partial Responder Patients With Genotype 1 Chronic Hepatitis C Infection
Status: Enrolling
Updated:  12/10/2013
Boehringer Ingelheim Investigational Site
2373
mi
from 98109
Philadelphia, PA
Drug Drug Interaction Study Between BI 201335 and BI 207127 in Chronic Hepatitis C Infected Patients
A Multi-centre, Open Label, Parallel Group Trial to Evaluate the Pharmacokinetic Interactions Between BI 207127 (600 mg t.i.d. or 600 mg b.i.d.) and BI 201335 (120 mg q.d.) Given in Combination With Ribavirin for 24 Weeks, and Their Combined Effect on the Pharmacokinetics of Tenofovir, Raltegravir, Caffeine (the Probe Drug Substrate for CYP1A2), Tolbutamide (the Probe Drug Substrate for CYP2C9) and Midazolam (the Probe Drug Substrate for CYP3A4) in Treatment naïve Patients and Prior Treatment Relapse or Partial Responder Patients With Genotype 1 Chronic Hepatitis C Infection
Status: Enrolling
Updated: 12/10/2013
Boehringer Ingelheim Investigational Site
2373
mi
from 98109
Philadelphia, PA
Click here to add this to my saved trials
Drug Drug Interaction Study Between BI 201335 and BI 207127 in Chronic Hepatitis C Infected Patients
A Multi-centre, Open Label, Parallel Group Trial to Evaluate the Pharmacokinetic Interactions Between BI 207127 (600 mg t.i.d. or 600 mg b.i.d.) and BI 201335 (120 mg q.d.) Given in Combination With Ribavirin for 24 Weeks, and Their Combined Effect on the Pharmacokinetics of Tenofovir, Raltegravir, Caffeine (the Probe Drug Substrate for CYP1A2), Tolbutamide (the Probe Drug Substrate for CYP2C9) and Midazolam (the Probe Drug Substrate for CYP3A4) in Treatment naïve Patients and Prior Treatment Relapse or Partial Responder Patients With Genotype 1 Chronic Hepatitis C Infection
Status: Enrolling
Updated:  12/10/2013
205.452.01001 Boehringer Ingelheim Investigational Site
701
mi
from 98109
Salt Lake City, UT
Drug Drug Interaction Study Between BI 201335 and BI 207127 in Chronic Hepatitis C Infected Patients
A Multi-centre, Open Label, Parallel Group Trial to Evaluate the Pharmacokinetic Interactions Between BI 207127 (600 mg t.i.d. or 600 mg b.i.d.) and BI 201335 (120 mg q.d.) Given in Combination With Ribavirin for 24 Weeks, and Their Combined Effect on the Pharmacokinetics of Tenofovir, Raltegravir, Caffeine (the Probe Drug Substrate for CYP1A2), Tolbutamide (the Probe Drug Substrate for CYP2C9) and Midazolam (the Probe Drug Substrate for CYP3A4) in Treatment naïve Patients and Prior Treatment Relapse or Partial Responder Patients With Genotype 1 Chronic Hepatitis C Infection
Status: Enrolling
Updated: 12/10/2013
205.452.01001 Boehringer Ingelheim Investigational Site
701
mi
from 98109
Salt Lake City, UT
Click here to add this to my saved trials
UCLA-Amity Parolee Health Promotion Study
Health Promotion Coaching/Vaccine for Homeless Parolees
Status: Enrolling
Updated:  1/8/2014
Amistad de Los Angeles
961
mi
from 98109
Los Angeles, CA
UCLA-Amity Parolee Health Promotion Study
Health Promotion Coaching/Vaccine for Homeless Parolees
Status: Enrolling
Updated: 1/8/2014
Amistad de Los Angeles
961
mi
from 98109
Los Angeles, CA
Click here to add this to my saved trials
Safety and Efficacy of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Interleukin-28B CC Allele-Positive Chronic Hepatitis C Virus (HCV) Genotype 1 Participants (P07755)
A Phase 3, Safety and Efficacy Study of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Chronic HCV Genotype 1 IL28B CC Subjects
Status: Enrolling
Updated:  1/16/2014
Clinical Research Facility
1103
mi
from 98109
Goodyear, AZ
Safety and Efficacy of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Interleukin-28B CC Allele-Positive Chronic Hepatitis C Virus (HCV) Genotype 1 Participants (P07755)
A Phase 3, Safety and Efficacy Study of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Chronic HCV Genotype 1 IL28B CC Subjects
Status: Enrolling
Updated: 1/16/2014
Clinical Research Facility
1103
mi
from 98109
Goodyear, AZ
Click here to add this to my saved trials
Safety and Efficacy of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Interleukin-28B CC Allele-Positive Chronic Hepatitis C Virus (HCV) Genotype 1 Participants (P07755)
A Phase 3, Safety and Efficacy Study of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Chronic HCV Genotype 1 IL28B CC Subjects
Status: Enrolling
Updated:  1/16/2014
Clinical Research Facility
1116
mi
from 98109
Phoenix, AZ
Safety and Efficacy of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Interleukin-28B CC Allele-Positive Chronic Hepatitis C Virus (HCV) Genotype 1 Participants (P07755)
A Phase 3, Safety and Efficacy Study of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Chronic HCV Genotype 1 IL28B CC Subjects
Status: Enrolling
Updated: 1/16/2014
Clinical Research Facility
1116
mi
from 98109
Phoenix, AZ
Click here to add this to my saved trials
Safety and Efficacy of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Interleukin-28B CC Allele-Positive Chronic Hepatitis C Virus (HCV) Genotype 1 Participants (P07755)
A Phase 3, Safety and Efficacy Study of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Chronic HCV Genotype 1 IL28B CC Subjects
Status: Enrolling
Updated:  1/16/2014
Clinical Research Facility
863
mi
from 98109
Bakersfield, CA
Safety and Efficacy of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Interleukin-28B CC Allele-Positive Chronic Hepatitis C Virus (HCV) Genotype 1 Participants (P07755)
A Phase 3, Safety and Efficacy Study of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Chronic HCV Genotype 1 IL28B CC Subjects
Status: Enrolling
Updated: 1/16/2014
Clinical Research Facility
863
mi
from 98109
Bakersfield, CA
Click here to add this to my saved trials
Safety and Efficacy of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Interleukin-28B CC Allele-Positive Chronic Hepatitis C Virus (HCV) Genotype 1 Participants (P07755)
A Phase 3, Safety and Efficacy Study of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Chronic HCV Genotype 1 IL28B CC Subjects
Status: Enrolling
Updated:  1/16/2014
Clinical Research Facility
1072
mi
from 98109
Chula Vista, CA
Safety and Efficacy of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Interleukin-28B CC Allele-Positive Chronic Hepatitis C Virus (HCV) Genotype 1 Participants (P07755)
A Phase 3, Safety and Efficacy Study of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Chronic HCV Genotype 1 IL28B CC Subjects
Status: Enrolling
Updated: 1/16/2014
Clinical Research Facility
1072
mi
from 98109
Chula Vista, CA
Click here to add this to my saved trials
Safety and Efficacy of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Interleukin-28B CC Allele-Positive Chronic Hepatitis C Virus (HCV) Genotype 1 Participants (P07755)
A Phase 3, Safety and Efficacy Study of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Chronic HCV Genotype 1 IL28B CC Subjects
Status: Enrolling
Updated:  1/16/2014
Clinical Research Facility
979
mi
from 98109
Long Beach, CA
Safety and Efficacy of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Interleukin-28B CC Allele-Positive Chronic Hepatitis C Virus (HCV) Genotype 1 Participants (P07755)
A Phase 3, Safety and Efficacy Study of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Chronic HCV Genotype 1 IL28B CC Subjects
Status: Enrolling
Updated: 1/16/2014
Clinical Research Facility
979
mi
from 98109
Long Beach, CA
Click here to add this to my saved trials
Safety and Efficacy of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Interleukin-28B CC Allele-Positive Chronic Hepatitis C Virus (HCV) Genotype 1 Participants (P07755)
A Phase 3, Safety and Efficacy Study of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Chronic HCV Genotype 1 IL28B CC Subjects
Status: Enrolling
Updated:  1/16/2014
Clinical Research Facility
972
mi
from 98109
San Bernardino, CA
Safety and Efficacy of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Interleukin-28B CC Allele-Positive Chronic Hepatitis C Virus (HCV) Genotype 1 Participants (P07755)
A Phase 3, Safety and Efficacy Study of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Chronic HCV Genotype 1 IL28B CC Subjects
Status: Enrolling
Updated: 1/16/2014
Clinical Research Facility
972
mi
from 98109
San Bernardino, CA
Click here to add this to my saved trials
Safety and Efficacy of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Interleukin-28B CC Allele-Positive Chronic Hepatitis C Virus (HCV) Genotype 1 Participants (P07755)
A Phase 3, Safety and Efficacy Study of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Chronic HCV Genotype 1 IL28B CC Subjects
Status: Enrolling
Updated:  1/16/2014
Clinical Research Facility
937
mi
from 98109
Ventura, CA
Safety and Efficacy of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Interleukin-28B CC Allele-Positive Chronic Hepatitis C Virus (HCV) Genotype 1 Participants (P07755)
A Phase 3, Safety and Efficacy Study of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Chronic HCV Genotype 1 IL28B CC Subjects
Status: Enrolling
Updated: 1/16/2014
Clinical Research Facility
937
mi
from 98109
Ventura, CA
Click here to add this to my saved trials
Safety and Efficacy of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Interleukin-28B CC Allele-Positive Chronic Hepatitis C Virus (HCV) Genotype 1 Participants (P07755)
A Phase 3, Safety and Efficacy Study of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Chronic HCV Genotype 1 IL28B CC Subjects
Status: Enrolling
Updated:  1/16/2014
Clinical Research Facility
2730
mi
from 98109
Miami, FL
Safety and Efficacy of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Interleukin-28B CC Allele-Positive Chronic Hepatitis C Virus (HCV) Genotype 1 Participants (P07755)
A Phase 3, Safety and Efficacy Study of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Chronic HCV Genotype 1 IL28B CC Subjects
Status: Enrolling
Updated: 1/16/2014
Clinical Research Facility
2730
mi
from 98109
Miami, FL
Click here to add this to my saved trials
Safety and Efficacy of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Interleukin-28B CC Allele-Positive Chronic Hepatitis C Virus (HCV) Genotype 1 Participants (P07755)
A Phase 3, Safety and Efficacy Study of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Chronic HCV Genotype 1 IL28B CC Subjects
Status: Enrolling
Updated:  1/16/2014
Clinical Research Facility
2730
mi
from 98109
Miami, FL
Safety and Efficacy of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Interleukin-28B CC Allele-Positive Chronic Hepatitis C Virus (HCV) Genotype 1 Participants (P07755)
A Phase 3, Safety and Efficacy Study of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Chronic HCV Genotype 1 IL28B CC Subjects
Status: Enrolling
Updated: 1/16/2014
Clinical Research Facility
2730
mi
from 98109
Miami, FL
Click here to add this to my saved trials
Safety and Efficacy of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Interleukin-28B CC Allele-Positive Chronic Hepatitis C Virus (HCV) Genotype 1 Participants (P07755)
A Phase 3, Safety and Efficacy Study of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Chronic HCV Genotype 1 IL28B CC Subjects
Status: Enrolling
Updated:  1/16/2014
Clinical Research Facility
1704
mi
from 98109
Springfield, IL
Safety and Efficacy of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Interleukin-28B CC Allele-Positive Chronic Hepatitis C Virus (HCV) Genotype 1 Participants (P07755)
A Phase 3, Safety and Efficacy Study of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Chronic HCV Genotype 1 IL28B CC Subjects
Status: Enrolling
Updated: 1/16/2014
Clinical Research Facility
1704
mi
from 98109
Springfield, IL
Click here to add this to my saved trials
Safety and Efficacy of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Interleukin-28B CC Allele-Positive Chronic Hepatitis C Virus (HCV) Genotype 1 Participants (P07755)
A Phase 3, Safety and Efficacy Study of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Chronic HCV Genotype 1 IL28B CC Subjects
Status: Enrolling
Updated:  1/16/2014
Clinical Research Facility
1939
mi
from 98109
Louisville, KY
Safety and Efficacy of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Interleukin-28B CC Allele-Positive Chronic Hepatitis C Virus (HCV) Genotype 1 Participants (P07755)
A Phase 3, Safety and Efficacy Study of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Chronic HCV Genotype 1 IL28B CC Subjects
Status: Enrolling
Updated: 1/16/2014
Clinical Research Facility
1939
mi
from 98109
Louisville, KY
Click here to add this to my saved trials
Safety and Efficacy of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Interleukin-28B CC Allele-Positive Chronic Hepatitis C Virus (HCV) Genotype 1 Participants (P07755)
A Phase 3, Safety and Efficacy Study of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Chronic HCV Genotype 1 IL28B CC Subjects
Status: Enrolling
Updated:  1/16/2014
Clinical Research Facility
2117
mi
from 98109
Pikeville, KY
Safety and Efficacy of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Interleukin-28B CC Allele-Positive Chronic Hepatitis C Virus (HCV) Genotype 1 Participants (P07755)
A Phase 3, Safety and Efficacy Study of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Chronic HCV Genotype 1 IL28B CC Subjects
Status: Enrolling
Updated: 1/16/2014
Clinical Research Facility
2117
mi
from 98109
Pikeville, KY
Click here to add this to my saved trials
Safety and Efficacy of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Interleukin-28B CC Allele-Positive Chronic Hepatitis C Virus (HCV) Genotype 1 Participants (P07755)
A Phase 3, Safety and Efficacy Study of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Chronic HCV Genotype 1 IL28B CC Subjects
Status: Enrolling
Updated:  1/16/2014
Clinical Research Facility
2328
mi
from 98109
Baltimore, MD
Safety and Efficacy of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Interleukin-28B CC Allele-Positive Chronic Hepatitis C Virus (HCV) Genotype 1 Participants (P07755)
A Phase 3, Safety and Efficacy Study of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Chronic HCV Genotype 1 IL28B CC Subjects
Status: Enrolling
Updated: 1/16/2014
Clinical Research Facility
2328
mi
from 98109
Baltimore, MD
Click here to add this to my saved trials
Safety and Efficacy of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Interleukin-28B CC Allele-Positive Chronic Hepatitis C Virus (HCV) Genotype 1 Participants (P07755)
A Phase 3, Safety and Efficacy Study of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Chronic HCV Genotype 1 IL28B CC Subjects
Status: Enrolling
Updated:  1/16/2014
Clinical Research Facility
1503
mi
from 98109
Kansas City, MO
Safety and Efficacy of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Interleukin-28B CC Allele-Positive Chronic Hepatitis C Virus (HCV) Genotype 1 Participants (P07755)
A Phase 3, Safety and Efficacy Study of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Chronic HCV Genotype 1 IL28B CC Subjects
Status: Enrolling
Updated: 1/16/2014
Clinical Research Facility
1503
mi
from 98109
Kansas City, MO
Click here to add this to my saved trials
Safety and Efficacy of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Interleukin-28B CC Allele-Positive Chronic Hepatitis C Virus (HCV) Genotype 1 Participants (P07755)
A Phase 3, Safety and Efficacy Study of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Chronic HCV Genotype 1 IL28B CC Subjects
Status: Enrolling
Updated:  1/16/2014
Clinical Research Facility
1503
mi
from 98109
Kansas City, MO
Safety and Efficacy of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Interleukin-28B CC Allele-Positive Chronic Hepatitis C Virus (HCV) Genotype 1 Participants (P07755)
A Phase 3, Safety and Efficacy Study of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Chronic HCV Genotype 1 IL28B CC Subjects
Status: Enrolling
Updated: 1/16/2014
Clinical Research Facility
1503
mi
from 98109
Kansas City, MO
Click here to add this to my saved trials
Safety and Efficacy of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Interleukin-28B CC Allele-Positive Chronic Hepatitis C Virus (HCV) Genotype 1 Participants (P07755)
A Phase 3, Safety and Efficacy Study of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Chronic HCV Genotype 1 IL28B CC Subjects
Status: Enrolling
Updated:  1/16/2014
Clinical Research Facility
1720
mi
from 98109
St. Louis, MO
Safety and Efficacy of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Interleukin-28B CC Allele-Positive Chronic Hepatitis C Virus (HCV) Genotype 1 Participants (P07755)
A Phase 3, Safety and Efficacy Study of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Chronic HCV Genotype 1 IL28B CC Subjects
Status: Enrolling
Updated: 1/16/2014
Clinical Research Facility
1720
mi
from 98109
St. Louis, MO
Click here to add this to my saved trials
Safety and Efficacy of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Interleukin-28B CC Allele-Positive Chronic Hepatitis C Virus (HCV) Genotype 1 Participants (P07755)
A Phase 3, Safety and Efficacy Study of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Chronic HCV Genotype 1 IL28B CC Subjects
Status: Enrolling
Updated:  1/16/2014
Clinical Research Facility
2400
mi
from 98109
New York, NY
Safety and Efficacy of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Interleukin-28B CC Allele-Positive Chronic Hepatitis C Virus (HCV) Genotype 1 Participants (P07755)
A Phase 3, Safety and Efficacy Study of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Chronic HCV Genotype 1 IL28B CC Subjects
Status: Enrolling
Updated: 1/16/2014
Clinical Research Facility
2400
mi
from 98109
New York, NY
Click here to add this to my saved trials
Safety and Efficacy of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Interleukin-28B CC Allele-Positive Chronic Hepatitis C Virus (HCV) Genotype 1 Participants (P07755)
A Phase 3, Safety and Efficacy Study of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Chronic HCV Genotype 1 IL28B CC Subjects
Status: Enrolling
Updated:  1/16/2014
Clinical Research Facility
2020
mi
from 98109
Cleveland, OH
Safety and Efficacy of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Interleukin-28B CC Allele-Positive Chronic Hepatitis C Virus (HCV) Genotype 1 Participants (P07755)
A Phase 3, Safety and Efficacy Study of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Chronic HCV Genotype 1 IL28B CC Subjects
Status: Enrolling
Updated: 1/16/2014
Clinical Research Facility
2020
mi
from 98109
Cleveland, OH
Click here to add this to my saved trials
Safety and Efficacy of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Interleukin-28B CC Allele-Positive Chronic Hepatitis C Virus (HCV) Genotype 1 Participants (P07755)
A Phase 3, Safety and Efficacy Study of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Chronic HCV Genotype 1 IL28B CC Subjects
Status: Enrolling
Updated:  1/16/2014
Clinical Research Facility
147
mi
from 98109
Portland, OR
Safety and Efficacy of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Interleukin-28B CC Allele-Positive Chronic Hepatitis C Virus (HCV) Genotype 1 Participants (P07755)
A Phase 3, Safety and Efficacy Study of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Chronic HCV Genotype 1 IL28B CC Subjects
Status: Enrolling
Updated: 1/16/2014
Clinical Research Facility
147
mi
from 98109
Portland, OR
Click here to add this to my saved trials
Safety and Efficacy of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Interleukin-28B CC Allele-Positive Chronic Hepatitis C Virus (HCV) Genotype 1 Participants (P07755)
A Phase 3, Safety and Efficacy Study of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Chronic HCV Genotype 1 IL28B CC Subjects
Status: Enrolling
Updated:  1/16/2014
Clinical Research Facility
1682
mi
from 98109
Dallas, TX
Safety and Efficacy of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Interleukin-28B CC Allele-Positive Chronic Hepatitis C Virus (HCV) Genotype 1 Participants (P07755)
A Phase 3, Safety and Efficacy Study of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Chronic HCV Genotype 1 IL28B CC Subjects
Status: Enrolling
Updated: 1/16/2014
Clinical Research Facility
1682
mi
from 98109
Dallas, TX
Click here to add this to my saved trials
Safety and Efficacy of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Interleukin-28B CC Allele-Positive Chronic Hepatitis C Virus (HCV) Genotype 1 Participants (P07755)
A Phase 3, Safety and Efficacy Study of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Chronic HCV Genotype 1 IL28B CC Subjects
Status: Enrolling
Updated:  1/16/2014
Clinical Research Facility
1682
mi
from 98109
Dallas, TX
Safety and Efficacy of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Interleukin-28B CC Allele-Positive Chronic Hepatitis C Virus (HCV) Genotype 1 Participants (P07755)
A Phase 3, Safety and Efficacy Study of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Chronic HCV Genotype 1 IL28B CC Subjects
Status: Enrolling
Updated: 1/16/2014
Clinical Research Facility
1682
mi
from 98109
Dallas, TX
Click here to add this to my saved trials
Safety and Efficacy of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Interleukin-28B CC Allele-Positive Chronic Hepatitis C Virus (HCV) Genotype 1 Participants (P07755)
A Phase 3, Safety and Efficacy Study of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Chronic HCV Genotype 1 IL28B CC Subjects
Status: Enrolling
Updated:  1/16/2014
Clinical Research Facility
1660
mi
from 98109
Fort Worth, TX
Safety and Efficacy of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Interleukin-28B CC Allele-Positive Chronic Hepatitis C Virus (HCV) Genotype 1 Participants (P07755)
A Phase 3, Safety and Efficacy Study of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Chronic HCV Genotype 1 IL28B CC Subjects
Status: Enrolling
Updated: 1/16/2014
Clinical Research Facility
1660
mi
from 98109
Fort Worth, TX
Click here to add this to my saved trials
Safety and Efficacy of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Interleukin-28B CC Allele-Positive Chronic Hepatitis C Virus (HCV) Genotype 1 Participants (P07755)
A Phase 3, Safety and Efficacy Study of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Chronic HCV Genotype 1 IL28B CC Subjects
Status: Enrolling
Updated:  1/16/2014
Clinical Research Facility
1890
mi
from 98109
Houston, TX
Safety and Efficacy of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Interleukin-28B CC Allele-Positive Chronic Hepatitis C Virus (HCV) Genotype 1 Participants (P07755)
A Phase 3, Safety and Efficacy Study of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Chronic HCV Genotype 1 IL28B CC Subjects
Status: Enrolling
Updated: 1/16/2014
Clinical Research Facility
1890
mi
from 98109
Houston, TX
Click here to add this to my saved trials
Safety and Efficacy of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Interleukin-28B CC Allele-Positive Chronic Hepatitis C Virus (HCV) Genotype 1 Participants (P07755)
A Phase 3, Safety and Efficacy Study of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Chronic HCV Genotype 1 IL28B CC Subjects
Status: Enrolling
Updated:  1/16/2014
Clinical Research Facility
701
mi
from 98109
Salt Lake City, UT
Safety and Efficacy of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Interleukin-28B CC Allele-Positive Chronic Hepatitis C Virus (HCV) Genotype 1 Participants (P07755)
A Phase 3, Safety and Efficacy Study of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Chronic HCV Genotype 1 IL28B CC Subjects
Status: Enrolling
Updated: 1/16/2014
Clinical Research Facility
701
mi
from 98109
Salt Lake City, UT
Click here to add this to my saved trials
Safety and Efficacy of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Interleukin-28B CC Allele-Positive Chronic Hepatitis C Virus (HCV) Genotype 1 Participants (P07755)
A Phase 3, Safety and Efficacy Study of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Chronic HCV Genotype 1 IL28B CC Subjects
Status: Enrolling
Updated:  1/16/2014
Clinical Research Facility
2429
mi
from 98109
Norfolk, VA
Safety and Efficacy of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Interleukin-28B CC Allele-Positive Chronic Hepatitis C Virus (HCV) Genotype 1 Participants (P07755)
A Phase 3, Safety and Efficacy Study of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Chronic HCV Genotype 1 IL28B CC Subjects
Status: Enrolling
Updated: 1/16/2014
Clinical Research Facility
2429
mi
from 98109
Norfolk, VA
Click here to add this to my saved trials
Safety and Efficacy of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Interleukin-28B CC Allele-Positive Chronic Hepatitis C Virus (HCV) Genotype 1 Participants (P07755)
A Phase 3, Safety and Efficacy Study of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Chronic HCV Genotype 1 IL28B CC Subjects
Status: Enrolling
Updated:  1/16/2014
Clinical Research Facility
2348
mi
from 98109
Richmond, VA
Safety and Efficacy of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Interleukin-28B CC Allele-Positive Chronic Hepatitis C Virus (HCV) Genotype 1 Participants (P07755)
A Phase 3, Safety and Efficacy Study of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Chronic HCV Genotype 1 IL28B CC Subjects
Status: Enrolling
Updated: 1/16/2014
Clinical Research Facility
2348
mi
from 98109
Richmond, VA
Click here to add this to my saved trials
Efficacy and Safety of Combination MK-5172 + MK-8742 + Ribavirin (RBV) in Genotype 2 Hepatitis C Infection (MK-5172-047)
A Phase II Clinical Trial to Study the Efficacy and Safety of a Combination Regimen of MK-5172 and MK-8742 With Ribavirin (RBV) in Subjects With Chronic Hepatitis C Genotype 2 Infection
Status: Enrolling
Updated:  2/14/2014
Clinical Research Facility
962
mi
from 98109
Los Angeles, CA
Efficacy and Safety of Combination MK-5172 + MK-8742 + Ribavirin (RBV) in Genotype 2 Hepatitis C Infection (MK-5172-047)
A Phase II Clinical Trial to Study the Efficacy and Safety of a Combination Regimen of MK-5172 and MK-8742 With Ribavirin (RBV) in Subjects With Chronic Hepatitis C Genotype 2 Infection
Status: Enrolling
Updated: 2/14/2014
Clinical Research Facility
962
mi
from 98109
Los Angeles, CA
Click here to add this to my saved trials
Efficacy and Safety of Combination MK-5172 + MK-8742 + Ribavirin (RBV) in Genotype 2 Hepatitis C Infection (MK-5172-047)
A Phase II Clinical Trial to Study the Efficacy and Safety of a Combination Regimen of MK-5172 and MK-8742 With Ribavirin (RBV) in Subjects With Chronic Hepatitis C Genotype 2 Infection
Status: Enrolling
Updated:  2/14/2014
Clinical Research Facility
1065
mi
from 98109
San Diego, CA
Efficacy and Safety of Combination MK-5172 + MK-8742 + Ribavirin (RBV) in Genotype 2 Hepatitis C Infection (MK-5172-047)
A Phase II Clinical Trial to Study the Efficacy and Safety of a Combination Regimen of MK-5172 and MK-8742 With Ribavirin (RBV) in Subjects With Chronic Hepatitis C Genotype 2 Infection
Status: Enrolling
Updated: 2/14/2014
Clinical Research Facility
1065
mi
from 98109
San Diego, CA
Click here to add this to my saved trials
Efficacy and Safety of Combination MK-5172 + MK-8742 + Ribavirin (RBV) in Genotype 2 Hepatitis C Infection (MK-5172-047)
A Phase II Clinical Trial to Study the Efficacy and Safety of a Combination Regimen of MK-5172 and MK-8742 With Ribavirin (RBV) in Subjects With Chronic Hepatitis C Genotype 2 Infection
Status: Enrolling
Updated:  2/14/2014
Clinical Research Facility
2099
mi
from 98109
New Orleans, LA
Efficacy and Safety of Combination MK-5172 + MK-8742 + Ribavirin (RBV) in Genotype 2 Hepatitis C Infection (MK-5172-047)
A Phase II Clinical Trial to Study the Efficacy and Safety of a Combination Regimen of MK-5172 and MK-8742 With Ribavirin (RBV) in Subjects With Chronic Hepatitis C Genotype 2 Infection
Status: Enrolling
Updated: 2/14/2014
Clinical Research Facility
2099
mi
from 98109
New Orleans, LA
Click here to add this to my saved trials
Efficacy and Safety of Combination MK-5172 + MK-8742 + Ribavirin (RBV) in Genotype 2 Hepatitis C Infection (MK-5172-047)
A Phase II Clinical Trial to Study the Efficacy and Safety of a Combination Regimen of MK-5172 and MK-8742 With Ribavirin (RBV) in Subjects With Chronic Hepatitis C Genotype 2 Infection
Status: Enrolling
Updated:  2/14/2014
Clinical Research Facility
2328
mi
from 98109
Baltimore, MD
Efficacy and Safety of Combination MK-5172 + MK-8742 + Ribavirin (RBV) in Genotype 2 Hepatitis C Infection (MK-5172-047)
A Phase II Clinical Trial to Study the Efficacy and Safety of a Combination Regimen of MK-5172 and MK-8742 With Ribavirin (RBV) in Subjects With Chronic Hepatitis C Genotype 2 Infection
Status: Enrolling
Updated: 2/14/2014
Clinical Research Facility
2328
mi
from 98109
Baltimore, MD
Click here to add this to my saved trials
Efficacy and Safety of Combination MK-5172 + MK-8742 + Ribavirin (RBV) in Genotype 2 Hepatitis C Infection (MK-5172-047)
A Phase II Clinical Trial to Study the Efficacy and Safety of a Combination Regimen of MK-5172 and MK-8742 With Ribavirin (RBV) in Subjects With Chronic Hepatitis C Genotype 2 Infection
Status: Enrolling
Updated:  2/14/2014
Clinical Research Facility
1908
mi
from 98109
Novi, MI
Efficacy and Safety of Combination MK-5172 + MK-8742 + Ribavirin (RBV) in Genotype 2 Hepatitis C Infection (MK-5172-047)
A Phase II Clinical Trial to Study the Efficacy and Safety of a Combination Regimen of MK-5172 and MK-8742 With Ribavirin (RBV) in Subjects With Chronic Hepatitis C Genotype 2 Infection
Status: Enrolling
Updated: 2/14/2014
Clinical Research Facility
1908
mi
from 98109
Novi, MI
Click here to add this to my saved trials
Efficacy and Safety of Combination MK-5172 + MK-8742 + Ribavirin (RBV) in Genotype 2 Hepatitis C Infection (MK-5172-047)
A Phase II Clinical Trial to Study the Efficacy and Safety of a Combination Regimen of MK-5172 and MK-8742 With Ribavirin (RBV) in Subjects With Chronic Hepatitis C Genotype 2 Infection
Status: Enrolling
Updated:  2/14/2014
Clinical Research Facility
1503
mi
from 98109
Kansas City, MO
Efficacy and Safety of Combination MK-5172 + MK-8742 + Ribavirin (RBV) in Genotype 2 Hepatitis C Infection (MK-5172-047)
A Phase II Clinical Trial to Study the Efficacy and Safety of a Combination Regimen of MK-5172 and MK-8742 With Ribavirin (RBV) in Subjects With Chronic Hepatitis C Genotype 2 Infection
Status: Enrolling
Updated: 2/14/2014
Clinical Research Facility
1503
mi
from 98109
Kansas City, MO
Click here to add this to my saved trials
Efficacy and Safety of Combination MK-5172 + MK-8742 + Ribavirin (RBV) in Genotype 2 Hepatitis C Infection (MK-5172-047)
A Phase II Clinical Trial to Study the Efficacy and Safety of a Combination Regimen of MK-5172 and MK-8742 With Ribavirin (RBV) in Subjects With Chronic Hepatitis C Genotype 2 Infection
Status: Enrolling
Updated:  2/14/2014
Clinical Research Facility
2409
mi
from 98109
Flushing, NY
Efficacy and Safety of Combination MK-5172 + MK-8742 + Ribavirin (RBV) in Genotype 2 Hepatitis C Infection (MK-5172-047)
A Phase II Clinical Trial to Study the Efficacy and Safety of a Combination Regimen of MK-5172 and MK-8742 With Ribavirin (RBV) in Subjects With Chronic Hepatitis C Genotype 2 Infection
Status: Enrolling
Updated: 2/14/2014
Clinical Research Facility
2409
mi
from 98109
Flushing, NY
Click here to add this to my saved trials
Efficacy and Safety of Combination MK-5172 + MK-8742 + Ribavirin (RBV) in Genotype 2 Hepatitis C Infection (MK-5172-047)
A Phase II Clinical Trial to Study the Efficacy and Safety of a Combination Regimen of MK-5172 and MK-8742 With Ribavirin (RBV) in Subjects With Chronic Hepatitis C Genotype 2 Infection
Status: Enrolling
Updated:  2/14/2014
Clinical Research Facility
2347
mi
from 98109
Limerick, PA
Efficacy and Safety of Combination MK-5172 + MK-8742 + Ribavirin (RBV) in Genotype 2 Hepatitis C Infection (MK-5172-047)
A Phase II Clinical Trial to Study the Efficacy and Safety of a Combination Regimen of MK-5172 and MK-8742 With Ribavirin (RBV) in Subjects With Chronic Hepatitis C Genotype 2 Infection
Status: Enrolling
Updated: 2/14/2014
Clinical Research Facility
2347
mi
from 98109
Limerick, PA
Click here to add this to my saved trials
Safety and Efficacy of GS-4774 for the Treatment of Chronic Hepatitis B
A Phase 2, Randomized, Open-Label Study to Evaluate the Safety and Efficacy of GS-4774 for the Treatment of Virally-Suppressed Subjects With Chronic Hepatitis B
Status: Enrolling
Updated:  2/26/2014
Dumont-UCLA Liver Transplant Center
958
mi
from 98109
Los Angeles, CA
Safety and Efficacy of GS-4774 for the Treatment of Chronic Hepatitis B
A Phase 2, Randomized, Open-Label Study to Evaluate the Safety and Efficacy of GS-4774 for the Treatment of Virally-Suppressed Subjects With Chronic Hepatitis B
Status: Enrolling
Updated: 2/26/2014
Dumont-UCLA Liver Transplant Center
958
mi
from 98109
Los Angeles, CA
Click here to add this to my saved trials
Safety and Efficacy of GS-4774 for the Treatment of Chronic Hepatitis B
A Phase 2, Randomized, Open-Label Study to Evaluate the Safety and Efficacy of GS-4774 for the Treatment of Virally-Suppressed Subjects With Chronic Hepatitis B
Status: Enrolling
Updated:  2/26/2014
Huntington Medical Research Institutes
957
mi
from 98109
Pasadena, CA
Safety and Efficacy of GS-4774 for the Treatment of Chronic Hepatitis B
A Phase 2, Randomized, Open-Label Study to Evaluate the Safety and Efficacy of GS-4774 for the Treatment of Virally-Suppressed Subjects With Chronic Hepatitis B
Status: Enrolling
Updated: 2/26/2014
Huntington Medical Research Institutes
957
mi
from 98109
Pasadena, CA
Click here to add this to my saved trials
Safety and Efficacy of GS-4774 for the Treatment of Chronic Hepatitis B
A Phase 2, Randomized, Open-Label Study to Evaluate the Safety and Efficacy of GS-4774 for the Treatment of Virally-Suppressed Subjects With Chronic Hepatitis B
Status: Enrolling
Updated:  2/26/2014
Kaiser Permanente
626
mi
from 98109
Sacramento, CA
Safety and Efficacy of GS-4774 for the Treatment of Chronic Hepatitis B
A Phase 2, Randomized, Open-Label Study to Evaluate the Safety and Efficacy of GS-4774 for the Treatment of Virally-Suppressed Subjects With Chronic Hepatitis B
Status: Enrolling
Updated: 2/26/2014
Kaiser Permanente
626
mi
from 98109
Sacramento, CA
Click here to add this to my saved trials
Safety and Efficacy of GS-4774 for the Treatment of Chronic Hepatitis B
A Phase 2, Randomized, Open-Label Study to Evaluate the Safety and Efficacy of GS-4774 for the Treatment of Virally-Suppressed Subjects With Chronic Hepatitis B
Status: Enrolling
Updated:  2/26/2014
Kaiser Permanente
1061
mi
from 98109
San Diego, CA
Safety and Efficacy of GS-4774 for the Treatment of Chronic Hepatitis B
A Phase 2, Randomized, Open-Label Study to Evaluate the Safety and Efficacy of GS-4774 for the Treatment of Virally-Suppressed Subjects With Chronic Hepatitis B
Status: Enrolling
Updated: 2/26/2014
Kaiser Permanente
1061
mi
from 98109
San Diego, CA
Click here to add this to my saved trials
Safety and Efficacy of GS-4774 for the Treatment of Chronic Hepatitis B
A Phase 2, Randomized, Open-Label Study to Evaluate the Safety and Efficacy of GS-4774 for the Treatment of Virally-Suppressed Subjects With Chronic Hepatitis B
Status: Enrolling
Updated:  2/26/2014
Kaiser Permanente
680
mi
from 98109
San Francisco, CA
Safety and Efficacy of GS-4774 for the Treatment of Chronic Hepatitis B
A Phase 2, Randomized, Open-Label Study to Evaluate the Safety and Efficacy of GS-4774 for the Treatment of Virally-Suppressed Subjects With Chronic Hepatitis B
Status: Enrolling
Updated: 2/26/2014
Kaiser Permanente
680
mi
from 98109
San Francisco, CA
Click here to add this to my saved trials
Safety and Efficacy of GS-4774 for the Treatment of Chronic Hepatitis B
A Phase 2, Randomized, Open-Label Study to Evaluate the Safety and Efficacy of GS-4774 for the Treatment of Virally-Suppressed Subjects With Chronic Hepatitis B
Status: Enrolling
Updated:  2/26/2014
Silicon Valley Research Institute
712
mi
from 98109
San Jose, CA
Safety and Efficacy of GS-4774 for the Treatment of Chronic Hepatitis B
A Phase 2, Randomized, Open-Label Study to Evaluate the Safety and Efficacy of GS-4774 for the Treatment of Virally-Suppressed Subjects With Chronic Hepatitis B
Status: Enrolling
Updated: 2/26/2014
Silicon Valley Research Institute
712
mi
from 98109
San Jose, CA
Click here to add this to my saved trials
Safety and Efficacy of GS-4774 for the Treatment of Chronic Hepatitis B
A Phase 2, Randomized, Open-Label Study to Evaluate the Safety and Efficacy of GS-4774 for the Treatment of Virally-Suppressed Subjects With Chronic Hepatitis B
Status: Enrolling
Updated:  2/26/2014
University of Miami
2730
mi
from 98109
Miami, FL
Safety and Efficacy of GS-4774 for the Treatment of Chronic Hepatitis B
A Phase 2, Randomized, Open-Label Study to Evaluate the Safety and Efficacy of GS-4774 for the Treatment of Virally-Suppressed Subjects With Chronic Hepatitis B
Status: Enrolling
Updated: 2/26/2014
University of Miami
2730
mi
from 98109
Miami, FL
Click here to add this to my saved trials
Safety and Efficacy of GS-4774 for the Treatment of Chronic Hepatitis B
A Phase 2, Randomized, Open-Label Study to Evaluate the Safety and Efficacy of GS-4774 for the Treatment of Virally-Suppressed Subjects With Chronic Hepatitis B
Status: Enrolling
Updated:  2/26/2014
Northwestern Memorial Hospital
1732
mi
from 98109
Chicago, IL
Safety and Efficacy of GS-4774 for the Treatment of Chronic Hepatitis B
A Phase 2, Randomized, Open-Label Study to Evaluate the Safety and Efficacy of GS-4774 for the Treatment of Virally-Suppressed Subjects With Chronic Hepatitis B
Status: Enrolling
Updated: 2/26/2014
Northwestern Memorial Hospital
1732
mi
from 98109
Chicago, IL
Click here to add this to my saved trials
Safety and Efficacy of GS-4774 for the Treatment of Chronic Hepatitis B
A Phase 2, Randomized, Open-Label Study to Evaluate the Safety and Efficacy of GS-4774 for the Treatment of Virally-Suppressed Subjects With Chronic Hepatitis B
Status: Enrolling
Updated:  2/26/2014
Digestive Disease Associates, PA
2325
mi
from 98109
Baltimore, MD
Safety and Efficacy of GS-4774 for the Treatment of Chronic Hepatitis B
A Phase 2, Randomized, Open-Label Study to Evaluate the Safety and Efficacy of GS-4774 for the Treatment of Virally-Suppressed Subjects With Chronic Hepatitis B
Status: Enrolling
Updated: 2/26/2014
Digestive Disease Associates, PA
2325
mi
from 98109
Baltimore, MD
Click here to add this to my saved trials
Safety and Efficacy of GS-4774 for the Treatment of Chronic Hepatitis B
A Phase 2, Randomized, Open-Label Study to Evaluate the Safety and Efficacy of GS-4774 for the Treatment of Virally-Suppressed Subjects With Chronic Hepatitis B
Status: Enrolling
Updated:  2/26/2014
Tufts Medical Center
2485
mi
from 98109
Boston, MA
Safety and Efficacy of GS-4774 for the Treatment of Chronic Hepatitis B
A Phase 2, Randomized, Open-Label Study to Evaluate the Safety and Efficacy of GS-4774 for the Treatment of Virally-Suppressed Subjects With Chronic Hepatitis B
Status: Enrolling
Updated: 2/26/2014
Tufts Medical Center
2485
mi
from 98109
Boston, MA
Click here to add this to my saved trials
Safety and Efficacy of GS-4774 for the Treatment of Chronic Hepatitis B
A Phase 2, Randomized, Open-Label Study to Evaluate the Safety and Efficacy of GS-4774 for the Treatment of Virally-Suppressed Subjects With Chronic Hepatitis B
Status: Enrolling
Updated:  2/26/2014
University of Michigan
1903
mi
from 98109
Ann Arbor, MI
Safety and Efficacy of GS-4774 for the Treatment of Chronic Hepatitis B
A Phase 2, Randomized, Open-Label Study to Evaluate the Safety and Efficacy of GS-4774 for the Treatment of Virally-Suppressed Subjects With Chronic Hepatitis B
Status: Enrolling
Updated: 2/26/2014
University of Michigan
1903
mi
from 98109
Ann Arbor, MI
Click here to add this to my saved trials